Company: CERO
Filing Date: 2025-11-20
Form Type: 424B3
Source: 0001213900-25-113118
Chunk: 17

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-20
Form: 424B3
Chunk 17
---
 PINK: CERO) (“CERo”, “Successor” or the “Company”), F/K/A Phoenix
Biotech Acquisition Corp. (“PBAX”) was incorporated in Delaware on June 8, 2021. PBAX was formed for the purpose of effecting
a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more
businesses (a “business combination”).

The Company is an innovative
immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. The Company’s
proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive
immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer
therapy. The Company is in early clinical development but has not yet begun product commercialization. The Company’s efforts will
focus on continued product development, including clinical development, to support regulatory approval to commercialize and subsequent
product commercialization.

In November 2024, the U.S. Food and Drug Administration (“FDA”)
cleared the Company’s Investigational New Drug Application for Phase 1 clinical trial of its lead compound, CER-1236, in acute myelogenous
leukemia (“AML”), and in May 2025 announced the first patient was dosed with CER-1236 in a Phase 1/1b trial of AML. In June
2025, the Company announced the completion of the initial evaluation of the first patient in its Phase 1/1b trial without any dose-limiting
toxicity and dosed the second AML patient in July 2025. In September 2025, the Company announced that it had dosed the third patient in
the starting dose cohort of its Phase 1 clinical trial evaluating CER-1236 in AML.

We submitted a second Investigational
New Drug (“IND”) application for the investigation of CER-T cell therapy in NSCLC and ovarian cancer, which was accepted by
the FDA on March 27, 2025.

Nasdaq Delisting -On October 29, 2025,
the Company received the determination of the Nasdaq Hearings Panel (the “Panel”) to deny the Company’s request to continue
the listing of its shares of common stock on Nasdaq and that the trading in the Company’s securities would be suspended at the open
of trading